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ABSTRACT
INK4A/ARF mutations are acquired in bcr/abl1 lymphoid blast phase chronic myelogenous leukemia (CML)
and bcr/abl1 acute lymphoblastic leukemia (ALL). Donor lymphocyte infusion and graft-versus-leukemia
(GVL) are generally ineffective in such ALLs, whereas GVL is highly active against bcr/abl1 CML, which
does not have a lesion in the INK4A/ARF locus. The mechanisms for the ineffectiveness of GVL are not fully
known, and it is possible that intrinsic resistance of acute lymphoid leukemias to immune effectors associated
with allogeneic GVL may contribute to ineffectiveness. This work tested the hypothesis that INK4A/ARF mu-
tations that are associated with transformation of bcr/abl1 CML to an ALL phenotype, and that are associated
with increased resistance to apoptosis render ALL cells insensitive to allogeneic immune responses tominor his-
tocompatibility antigens (mHA). Murine acute pre-B ALLs were induced by transfer of the human p210 bcr/abl
gene into bone marrow of INK4A/ARF null mice. These ALL lines were then studied in a murine model of
MHC-matched, mHA-mismatched allogeneic BMT. In vivo growth of these ALLs was inhibited in allogeneic
transplants characterized by active allogeneic immune responses compared to their behavior in syngeneic trans-
plants. In vitro ALLswith INK4A/ARF, p210 bcr/abl, or p190 bcr/abl mutations remained sensitive to anti-mHA
cytolytic T cells. In addition, the ALLs were capable of inducing primary immune responses to mHAs in vivo.
Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses,
suggesting that active immunotherapies againstmHAhave the potential to control such acute lymphoblastic leu-
kemias.
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Bcr/abl mutations are the defining genetic feature
in chronic myelogenous leukemia (CML). The natu-
ral history of CML is that the leukemia can persist for
a long period like a chronic disease, but that it even-
tually acquires additional genetic lesions and is trans-
formed into an acute leukemia, either lymphoid or
myeloid. Allogeneic hematopoietic stem cell trans-
plantation is a potentially curative treatment of choice
for patients with CML. Clinical studies involving
transplant have demonstrated that the allogeneic622graft-versus-leukemia (GVL) effect is extremely po-
tent in chronic phase CML; relapses after allogeneic
transplant are relatively uncommon, and many re-
lapses can be effectively treated with infusion of
donor lymphocytes. In contrast, GVL is negligible
when CML converts to an acute lymphoid blast phase
[1-4]. The mechanisms of this insensitivity to immune
control are not fully understood, and multiple hy-
potheses have been advanced [5]. A single explanation
is unlikely, and mechanisms may ultimately prove to
be related to particular mutations within classes of
High-Risk Acute Lymphoblastic Leukemia Cells 623leukemias. One hypothesis we have considered is that
mutations that are acquired by leukemias that drive it
toward an acute lymphoid phenotype may also render
the leukemia cell intrinsically resistant to effector
cells that mediate GVL.
Remarkably, INK4A/ARF mutations occur in
50% of cases of lymphoid blast crisis of CML [6]. In
addition, 1/4 of bcr/abl1 acute lymphoblastic leukemia
(ALL) cases also have lesions near the INK4A/ARF
locus [7,8]. The INK4A/ARF locus contains 2 tumor
suppressors that have separate promoters but share
exons. Mutations or deletions within this gene locus
can impact the negative regulation of Rb-mediated
cell cycle progression (INK4A) and p53 degradation
(ARF), and are associated with both murine and hu-
man carcinogenesis [9,10]. In addition, loss of function
in the INK4A/ARF locus also renders lymphocytes
resistant to induction of apoptosis from a variety of
stimuli [11,12]. These observations suggest the hy-
pothesis that INK4A/ARF null, bcr-abl1 ALL cells
are intrinsically resistant to GVL effectors possibly
because of apoptotic resistance.
We have employed a murine model that provides
an opportunity to test this hypothesis. Pre-B ALLs
have been induced by insertion of human bcr/abl
cDNAs into nonmalignant marrow cells of INK4A/
ARF null mice. The leukemias have a short latency,
and in vivo behave like human ALL. The leukemias
are on a C57BL/6 background that allows us to exploit
our well-characterized model of MHC-matched, mi-
nor histocompatibility antigen (mHA) mismatched
BMT in which mHA antigens have been characterized
at a genetic and peptide level.
MATERIALS AND METHODS
Mice
The C57BL/6 INK4A/ARF null mouse carries
a deletion of the INK4A/ARF locus eliminating genes
for both p16 (INK4A) and p19 (ARF) (National
Cancer Institute, Frederick, MD) [13]. C3.SW mice
(Jackson) were transplant donors and C57BL/6 mice
(National Cancer Institute) were recipients. The
mice are MHC antigen matched (H2b) but mHA
mismatched at many loci (H1, H3, H7, H8, H9,
and H13). C3.SW are H2b and were derived from
an 11 generation back cross of C3H against a nonin-
bred H2b donor strain [14].
Cell Lines
Table 1 summarizes relevant features of the leuke-
mia cell lines used in these experiments. Primary mar-
row cells from INK4A/ARF null mice were transduced
with a retroviral vector encoding the human p210 bcr/
abl cDNA [15]. The MSCV-BCR/ABL-IRES-GFP
vector was kindly provided by Dr. Richard Van Etten.
The neo gene was removed from this vector by diges-tion with Nco I and Cla I, and the YFP gene was in-
serted by standard cloning procedure to yield the
MSCV-Nup98/HoxA9-YFP vector used in the pres-
ent study. Retroviral vector plasmids were transfected
into phoenix-eco cells (ATCC, Rockville, MD) using
lipofectamine 2000 per manufacturer’s instructions
(10 mg DNA per 100,000 cells in a 6-well tissue culture
dish). At 36 hours posttransfection, viral supernatants
were collected, filtered, and stored at280C. Retrovi-
rus-treatedmarrow cells (2 105) were infused i.v. into
irradiated (600 cGy) C57BL/6 recipients and sponta-
neous ALL emerged within 3 weeks. NSTY lines
were derived by in vitro culture of splenocytes from
these leukemia bearing mice; no cytokine supplemen-
tation was required [16,17]. The male acute myeloge-
nous leukemia line (AML-m) was derived from
a C57BL/6 male infused with wild-type male
C57BL/6 marrow transduced in vitro with vectors en-
coding p210 bcr/abl and NUP98/HOXA9 [15,18].
C1498 (ATCC) is a spontaneous C57BL/6 acute
NKT cell leukemia [19]. ASLN cells were derived
from aC57BL/6 transgenicmouse created by insertion
of a C57BL/6 oocyte of a human p190 bcr/abl cDNA
under the control of the immunoglobulin heavy chain
enhancer E-mu and the murine Mb-1 promoter. YAC
(TIB-160, ATCC) is an A/Sn strain lymphoma line
that is sensitive to NK cells and is the conventional tar-
get in murine NK cytolysis assays. P815 cells are
a DBA/2 strain (H2d) mastocytoma (TIB-64, ATCC).
Bone Marrow Transplant
Following 1100 cGy total body irradiation (TBI;
given in 2 equal divided doses 14-16 hours apart) and
i.p. 5-fluoruracil (125 mg/kg) C57BL/6 recipients
were infused with 4  106 marrow cells plus 10 
106 splenocytes from normal C57BL/6 mice or
C3.SWmice immunized against C57BL/6 splenocytes
[20-22]. They were housed in conventional rooms with
food and water ad libitum. From 2 days before bone
marrow transplantation (BMT) until day 14, the water
was acidified (pH 2.5) and supplemented with 2 g/L
neomycin sulfate (Sigma, St. Louis, MO). We and




NSTY-1 pre-B ALL p210 Yes Female
NSTY-6 pre-B ALL p210 Yes Male









ASLN pre-B ALL p190 No Female
C1498 NKT Normal Unknown Female
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C3.SW donors (with 5-10  106 T cells in the graft)
and C57BL/6 recipients fatal graft-versus-host disease
(GVHD) is observed in a significant number of recip-
ients over a 6-week period [22]. In experiments in
which leukemia progression in vivo was measured
C57BL/6 mice underwent myeloablation with radia-
tion and 5-FU and then were simultaneously infused
with 4  106 bone marrow cells, 1  107 splenocytes,
and 1 104 NSTY-1 ALL cells. The source of spleno-
cytes varied between experimental groups with some
recipients receiving marrow and spleen cells from
C3.SW mice that had been vaccinated against
C57BL/6 splenocytes to enhance alloreactivity,
whereas other control mice received cells from
C3.SW that had not been vaccinated or from normal
C57BL/6 mice.
Generation of Alloreactive T Cells
C3.SW mice were vaccinated s.c. with 107 25 Gy
irradiated splenocytes 2 to 3 times at 2-week intervals.
Splenocytes from C3.SW mice immunized against
C57BL/6 splenocytes were restimulated in vitro 4
days at a 5:3 ratio at 107 cells/mL with 25 Gy-irradi-
ated C57BL/6 splenocytes that express all the known
minor histocompatibility antigens. In other experi-
ments designed to generate CTL with a single speci-
ficity for 1 minor antigen peptide C3.SW responder
cells were stimulated with syngeneic C3.SW spleno-
cytes preincubated with exogenous minor histocom-
patibility antigen peptide. Cells were incubated at
37C in R10S media (RPMI, 10% FCS, 200 mM glu-
tamine, 104 U/mL penicillin/streptomycin, nonessen-
tial amino acids (1 mL per 100 mL medium), 100 mM
Na pyruvate, 50 mM beta-mercaptoethanol). No cy-
tokines were added to the culture [23]. T cells gener-
ated from these cultures were used as effector cells
with target leukemia cells and a flow cytometry based
leukemia cell inhibition assay was used to measure the
capacity of the effector cells to inhibit the leukemia
target cells.
Natural Killer (NK) Cells
NK cells were selected from freshly isolated sple-
nocytes using positive selection with paramagnetically
labeled DX5 monoclonal antibody (mAb; Miltenyi,
Auburn, CA). NK cells were then directly placed as ef-
fector cells in the in vitro leukemia cell inhibition as-
says. In some experiments mice were injected i.p.
twice at 24-hour intervals with 100 mg of polyI:C
(Sigma) in 0.5-mL sterile PBS. DX5-positive cells
were selected 1 day after the second injection. Isolated
NK cells were used as effector cells with target leuke-
mia cells, and a flow cytometry-based leukemia cell in-
hibition assay was used to measure the capacity of the
effector cells to inhibit the leukemia target cells.Leukemia Cell Inhibition Assay
The assay measures the relative size of leukemia
target cell populations cocultured for 3 days with po-
tential cytolytic effector cells in microcultures in 96-
well plates. Five thousand target cells were placed
with effector cells at specified effector-to-target cells
ratios. Following 3 days of culture 4000 fluorescent
microbeads were added to each well, and immediately
thereafter the well was harvested and examined flow
cytometrically. Regions were defined corresponding
to the beads and viable leukemia cells and the number
of events in each region was recorded. The number of
viable leukemia cells in a well was calculated using the
following formula: (leukemia cells in well)5 (leukemia
cells counted) (constant number of fluorescent beads
added to well/number of fluorescent beads counted).
The percent leukemia cells surviving in wells with ef-
fector cells was calculated with the following formula:
Percent leukemia cells surviving 5 (number of leuke-
mia cells in well with effectors/number of leukemia
cells in wells without effector cells)  100. Duplicates
or triplicates of each condition were measured.
ELISPOT
Splenocytes (106) were added to wells preincu-
bated with IFN-g capture antibody and stimulated
for 48 hours with HY peptides (Uty, Dby, and Smcy)
or irrelevant peptide (WPRPQIPP) (5 mg/well)
[23,24]. IFN-g release was detected with biotinylated
anti-IFN-g antibody (Caltag, Carlsbad, CA) and
streptavidin peroxidase [24].
Flow Cytometry
Conventional analytic flow cytometry was per-
formed using a Becton Dickinson FACScan with anal-
ysis performed by Cellquest software or WinMDI.
Directly labeled mAbs for the cell surface markers
specified in the text were obtained from Pharmingen
(San Diego, CA) or Caltag.
RESULTS
Introduction of the p210 bcr-abl Gene into INK4A/
ARF Null Bone Marrow Produces pre-B ALL
Like Williams et al. [10] we have observed that in-
sertion of a human p210 bcr-abl cDNA into marrow of
INK4A/ARF null mice induces acute leukemias in
vivo. The leukemias (NSTY) grow well in vitro with-
out cytokine support. They express B lineage markers
(B2201, CD191), but are negative for T cell (CD32),
granulocyte (Gr-12), monocyte (CD11b2), and ery-
throid (Ter1192) markers (Figure 1). They express
MHC I (H2-D1 and H2-K1), but are negative for
MHC II (Ia) and surface immunoglobulin (data not
shown). In addition, the detailed surface antigen ex-
pression profile surface is characteristic of murine
late pro-B/early pre-B cells [25,26]: AA4.11, IL7R1,
High-Risk Acute Lymphoblastic Leukemia Cells 625Figure 1. Flow cytometric phenotype of the p210 bcr/abl1, INK4A/ARF null acute lymphoblastic leukemia. Bone marrow from INK4A/ARF
null mice developing acute leukemia following injection of p210 bcr/abl GFP1 retrovirus-treated syngeneic bone marrow was assessed by flow
cytometry. GFP is on the Y-axis and identifies leukemia cells expressing bcr/abl. (The bcr/abl vector coexpresses GFP through an IRES element,
and thus GFP can be used as a marker gene for vector expressing cells.) Staining with fluorochrome-labeled monoclonal antibodies specific for
various hematopoietic cell surface markers is displayed on the X-axis.c-Kit2, CD431/2, CD21 (data not shown). When 104
NSTY-1 cells are intravenously injected into normal
C57BL/6, 100% of mice develop leukemia within 3
weeks with infiltration of marrow, blood, spleen, and
brain.
Growth of p210 bcr/abl1 INK4A/ARF Null Acute
pre-B ALL Cells (NSTY) Is Inhibited in Recipients
Undergoing Bone Marrow Transplantation with
Alloreactive Grafts
A simple but direct test of the hypothesis that
INK4A/ARF null leukemias are resistant to immune
effectors is to compare their progression from a state
of minimal residual disease at the time of bone marrow
transplant in transplant recipients experiencing allo-
reactivity with that in groups that experience less allo-
reactivity. If the leukemias were intrinsically resistant
to allogeneic effects, the rate of leukemia progression
and time to mortality from leukemia should be similar
among the transplant groups. We tested this in a well-
characterized model of MHC-matched, mHA-mismatched transplant. C3.SW donors primed against
C57BL/6 splenocytes generate anti-C57BL/6 T cell
responses including peptide-epitope defined CD8 T
cell responses directed against mHAs H7, H3, and
H13 [23]. Such vaccination substantially increases
the alloreactivity of the donor graft [22]. Two control
groups that have much less alloreactivity were also
studied: unprimed C3.SW donors or normal C57BL/
6 donors. In the transplants normal C57BL/6 females
were transplanted with cells from either syngeneic
normal C57BL/6, unprimed C3.SW, or C3.SW previ-
ously primed against C57BL/6. To establish a uniform
burden of minimal residual disease, 1  104 NSTY-1
acute leukemia cells were mixed with each graft and in-
fused on the day of transplant. Recipients in the con-
trol groups died of progressive leukemia within 14
days. In contrast, mice receiving primed allogeneic
grafts exhibited prolonged survival (Figure 2). Leuke-
mia burden was assessed by flow cytometry on periph-
eral blood and/or marrow in randomly selected mice
from either cohort at 14 days. In syngeneic transplants
626 F. M. Young et al.(sampled mice n 5 3) marrow leukemia content was
65% 6 4% (average 6 SEM), significantly greater
than in the primed allogeneic transplant group (sam-
pled mice n 5 6) where it was 16% 6 6% (P\ .001
Figure 2. Mice receiving allogeneic transplant survive longer with
the acute lymphoblastic leukemia compared to controls receiving
syngeneic transplant. Following myeloablation C57BL/6 mice
were simultaneously infused with 4  106 bone marrow cells, 1 
107 splenocytes, and 1 104 NSTY-1 acute lymphoblastic leukemia
cells (to establish a uniform burden of minimal residual disease) on
the day of transplant. ‘‘Primed allogeneic’’ mice (n 5 19) received
marrow and spleen cells from C3.SWmice that had been vaccinated
against C57BL/6 splenocytes (not NSTY-1) to enhance alloreactiv-
ity. ‘‘Unprimed allogeneic’’ mice (n 5 14) received cells from
C3.SW that had not been vaccinated. ‘‘Syngeneic’’ mice (n5 17) re-
ceived cells from normal C57BL/6mice.Mice were followed for sur-
vival for up to 1 month and then were sacrificed. Flow cytometry
performed on blood and marrow from samples from each group
demonstrated NSTY-1 cells in animals that appeared ill. Data are
pooled from 3 experiments. Survival proportions were compared us-
ing the log rank test.by 2-tailed unpaired t test). Surviving animals were
euthanized at 4 weeks, 2 weeks after the last animal
in the syngeneic group had died. Leukemia cell con-
tent in marrow was measured in 2 of these mice, with
0.3% and 5% leukemia cells detected (data not shown).
Histological assessment of animals for GVHDwas not
performed because the purpose of the experiment was
to measure the rate of leukemia progression in the 2
environments, and because other published work
from our lab has shown that fatal GVHD is consis-
tently observed at 5-10 weeks using this transplant
protocol [22].
Susceptibility to mHA Antigen-Specific
Allogeneic T Cells
The slower progression of the pre-B leukemias
suggested that INK4A/ARF null leukemia cells were
sensitive to some component of the allogeneic re-
sponse. Within this transplant model CD8 mHA-
specific T cells play a significant role in the allogeneic
response. In our transplant model the donor C3.SW
and recipient C57BL/6 mHA differences at H3, H7,
and H13 are defined at a peptide level, and peptide-
specific CD8 CTLs can be readily generated. We
tested the hypothesis that INK4A/ARF null leukemia
cells remain sensitive to such mHA-specific CD8 T
cells. Primed C3.SW donor or naı¨ve C57BL/6 spleno-
cytes were stimulated in vitro with mHA peptides and
used as effectors in leukemia inhibition assays in vitro.
Donor strain allogeneic T cells significantly inhibited
the growth of INK4A/ARF null leukemia cells, while
syngeneic T cells did not (Figure 3A). The sensitivity
of NSTY-1 was similar to that of C1498, anotherFigure 3. Sensitivity of acute lymphoblastic leukemia cells to allogeneic alloreactive T cells. Leukemia cell inhibition assays were performed
using alloreactive T cells from C3.SW mice immunized against C57BL/6 splenic allogeneic minor histocompatibility antigens as effectors.
In (A), female NSTY-1 were the leukemia targets, whereas in (B), C1498 cells were the targets. Leukemia cells were cocultured with alloreactive
T cells for 48 hours and leukemia cell number was compared to the number of leukemia cells in wells that did not have T cells. ‘‘Allogeneic’’
effectors were derived from allogeneic C3.SWmice previously sensitized to C57BL/6 splenocytes, whereas ‘‘syngeneic’’ effectors were from nor-
mal syngeneic C57BL/6 splenocytes. Effector cells had been restimulated in vitro with a single mHA peptide (H3, H7, or H13) prior to their use
in the leukemia cell inhibition assays. Each condition was performed in duplicate in this experiment performed once. Error bars represent stan-
dard error of the mean. Inhibition with allogeneic cells was compared to inhibition with syngeneic cells. In all comparisons P\ .05 by 2-tailed
unpaired t test with the exception of C1498 target 12.5:1, where P 5 .056.
High-Risk Acute Lymphoblastic Leukemia Cells 627C57BL/6 NKT leukemia line known to be sensitive to
mHA-specific T cells (panel 3B).
We extended these experiments examining intrin-
sic resistance of p2101 bcr/abl INK4A/ARF null ALL
leukemia cells by comparing their sensitivity to CTLs
to that of p2101 bcr/abl AML cells induced in normal
C57BL/6 mice. Figure 4 demonstrates that the sensi-
tivity profiles of the ALL and AML lines were very
similar.
These experiments had suggested that neither the
p210 bcr/abl nor the INK/ARF mutations conferred
substantial resistance to CTLs. Although the p210
bcr/abl mutation is the most common, a substantial
number of bcr/abl1 ALLs harbor an alternative muta-
tion, the p190 bcr/abl. We assessed the sensitivity of
a p190 bcr/abl ALL line (ASLN) and observed that
its sensitivity to anti-mHA CTLs was very similar to
that of the control C1498 leukemia line (Figure 5).
In additional experiments we positively selected CD8
and CD4 T cells from alloreactive donors and used
them as effectors in leukemia cell inhibition assays.
The CD8 fractions were significantly more potent
than CD4 fractions in inhibition of both ASLN and
NSTY-1 ALL lines; however, the CD4 fraction still
Figure 4. p210 bcr/abl1 INK4A/ARFnull pre-B ALL cells and p210
bcr/abl1 AML cells exhibit similar sensitivity to allogeneic alloreac-
tive T cells. Leukemia cell inhibition assays were performed using
NSTY-1 or AML-f leukemia cells as targets. Effector cells were gen-
erated in vitro using intact C57BL/6 splenocytes because these cells
express all of the known minor histocompatibility antigens. Either
primed allogeneic C3.SW or normal syngeneic C57BL/6 spleno-
cytes were restimulated in vitro for 4 days and then used as effector
cells. The experiment was performed once. Each condition was per-
formed in triplicate. Error bars represent standard error of the mean.
Inhibition with allogeneic cells was compared to inhibition with syn-
geneic cells. In all comparisons P\ .01 by 2-tailed unpaired t test
with the exception of AML-f target at 25:1, where P 5 .78. mediated some inhibition of the leukemia cells. Nei-
ther T cell population inhibited the unrelated DBA/2
strain (H2d) P815 mastocytoma (Figure 6).
NK cells emerge early after allogeneic transplant,
and could play a significant role in controlling leuke-
mia in the early posttransplant period. We examined
the sensitivity of the leukemia cell lines to NK cells.
Neither the NSTY-1 ALL (p210 bcr/abl1, INK4A/
ARF null) nor the ASLN ALL (p190 bcr/abl1) were
inhibited in vitro by NK cells, unlike the NK sensitive
YAC control cells (Figure 7). The AML-f cells (p210
bcr/abl1, INK4/ARF normal) exhibited modest sensi-
tivity to NK cells.
Pre-B ALL Cells with the p210 bcr/abl and INK4A/
ARF Mutations Are Capable of Inducing Primary
T Cell Responses In Vivo
Although the studies clearly demonstrated that the
ALL cells were not intrinsically or even relatively resis-
tant to allogeneic cytolytic T cells, it remained possible
that the combinations of mutations had rendered the
cells incapable of effective priming of an immune re-
sponse. This would be an alternate hypothesis for
explaining the poor immune control of ALL. Leuke-
mia-specific antigens have not been functionally or
molecularly defined to date in our ALL models, and
Figure 5. p190 bcr/abl1 pre-B ALL cells exhibit sensitivity to allo-
geneic alloreactive T cells. Leukemia cell inhibition assays were per-
formed using pre-B ASLN or C1498 leukemia cells as targets.
Effector T cells were from short-term cultures in which irradiated
C57BL/6 splenocytes were used to restimulate spleen cells from ei-
ther allogeneic C3.SW mice immunized against normal C57BL/6
splenocytes or from normal C57BL/6 mice. Similar results for
ASLNhave been seen in 3 leukemia inhibition assays. Error bars rep-
resent standard error of the mean. Values for allogeneic were com-
pared to syngeneic for each effector to target ratio. In all
comparisons P\ .002 by 2-tailed unpaired t test.
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putative antigens independent of responses to widely
distributed minor histocompatibility antigens is not
yet feasible. To circumvent this technical obstacle we
chose to employ a physiologically relevant leukemia
cell surrogate antigen. T cell responses to male histo-
compatibility antigens (HY) can be induced and readily
measured in femalemice, andprovide a straightforward
experimental approach for testing this alternate hy-
pothesis. Live male leukemia cells were injected intra-
venously and 2 weeks later IFN-g release in response
to HY peptides was directly assessed in freshly isolated
splenocytes. Male bcr/abl1 AML cells that are known
to elicit a male mHA HY-antigen specific T cell re-
sponse in vivo were used as a positive control.We com-
pared 2 male NSTY lines (NSTY-6 and NSTY-7) to
this control (AML-m). Normal female C57BL/6
mice were injected with 104 male leukemia cells, and
naı¨ve female C57BL/6 served as a negative control.
Two weeks later splenocytes were assayed directly in
IFN-gELISPOTusingHY peptide antigens. Figure 8
demonstrates a clear primary HY specific response in
normal mice injected with male NSTY-6 or NSTY-7
cells.
Figure 6. Inhibition of NSTY-1 and ASLN by alloreactive CD8 and
CD4 T cells. Spleen cells from a donor strain C3.SW mouse previ-
ously vaccinated against recipient strain C57BL/6 spleen cells were
restimulated in vitro with irradiated C57BL/6 spleen cells for 4
days. CD4 and CD8 T cells were positively selected from the cul-
tures using paramagnetically labeled monoclonal antibodies (Milte-
nyi) and used as effector cells at a 10:1 effector:target ratio in
a leukemia inhibition assay. Percent viable leukemia cells is plotted
versus control leukemia cells not incubated with T cells. One of 3
similar experiments is presented. Mean and standard error of the
mean are shown. Both CD8 and CD4 fractions inhibited ASLN
and NSTY (P \ .001 by 2-tailed unpaired t test), whereas P815
was not inhibited by either. CD8 inhibition was significantly greater
than CD4 inhibition for both ASLN and NSTY (P\ .01 by 2-tailed
unpaired t test). DX51 NK cells represented\0.6% of the prepur-
ification samples and\0.4% of the postpurification samples. The
postpurification CD4 fraction contained only 1.3% CD8 cells.
The postpurification CD8 fraction contained only 3.1% CD4 cells.DISCUSSION
These studies examined potential mechanisms for
the relative ineffectiveness of allogeneic donor lympho-
cyte infusion and allogeneic GVL effects in pre-B ALL
that harbor bcr/abl and INK4A/ARF mutations, com-
mon high-risk genetic lesions in human ALL. Specifi-
cally, experiments using murine leukemias induced by
humanmutations tested the hypothesis that such muta-
tions render leukemias resistant to allogeneic effectors.
Both in vivo and in vitro p210 bcr/abl1, INK4A/ARF
null ALL lines were inhibited by allogeneic immune ef-
fectors. The leukemias remained exquisitely sensitive to
allogeneic T cells directed against minor histocompati-
bility antigens. ALL cells harboring the p190 bcr/abl
mutation also remained sensitive to anti-mHA T cells.
The sensitivity of the p210 bcr/abl1 ALLs was similar
to p210 bcr/abl1 AMLs, contrary to results in clinical
transplantation in which more potent GVL effects are
observed in AML compared to ALL. In addition, we
demonstrated that in vivo theALLcells could effectively
induce T cell responses to antigens in the ALL cells.
There are several limitations to these studies. First,
the experiments examined the sensitivity of the leuke-
mias to widely distributed minor histocompatibilty
antigens, rather than hematopoietic-specific or
leukemia-specific T cell responses. Thus, it remains
conceivable that although the ALLs remain sensitive
to T cells directed against these ubiquitous mHA,
they may be resistant to T cells directed against
Figure 7. p210 bcr/abl1, INK4A/ARF pre-B ALL (NSTY-1), and
p190 bcr/abl1 pre-B ALL (ASLN) do not exhibit sensitivity to NK
cells in vitro. Acute leukemia lines were assessed for sensitivity to
NK cells in vitro in leukemia cell inhibition assays. Yac cells, a known
NK-sensitive cell line, were used as positive control targets. NK cells
were directly isolated from female C57BL/6 mice and used at 100:1
effector to target cell ratios. Mice were not pretreated with poly I:C.
One of 3 representative experiments is presented. Error bars repre-
sent standard error of the mean. Two-tailed unpaired t test was
used to determine if the mean for each cell line was\100% (ie, sig-
nificantly reduced byNK cells). Both Yac (P\ .005) and AML-f (P\
.022) were inhibited by NK cells. NSTY-1, ASLN, and C1498 were
not inhibited by NK cells.
High-Risk Acute Lymphoblastic Leukemia Cells 629tissue-specific or leukemia-specific antigens. How-
ever, such resistance would not be related to lack of
MHC class I expression, resistance to CTL effector
mechanisms, blockade to induction of apoptosis, or in-
ability to present antigens in general. The experimen-
tal model effectively rules out these mechanisms.
Untested is the possibility that the ALLs fail to synthe-
size and present potential hematopoietic antigens. We
cannot test this hypothesis because we do not know the
nature of such antigens and the nature of T cell re-
sponses to such antigens in this model. Second, the ex-
periments assessing the rates of leukemia progression
in the allogeneic transplants (Figure 1) did not charac-
terize the GVHD in vivo. This was a conscious deci-
sion of experimental design based on years of
experience with this model in which GVHD is reliably
induced and GVHD-related mortality occurs in 6-8
weeks. Our goal was not to determine if there would
be long-term survivors of the transplants or if leuke-
mia-selective GVL could be induced. Rather, the
goal of the experiments was to determine if the leuke-
mias with the specific human genetic mutations were
intrinsically resistant to allogeneic effects.
Thus, contrary to commonbelief [1-4] ALL remain
susceptible to alloreactive donor T cells and can stimu-
late mHA specific T cell responses in vivo, suggesting
Figure 8.Acute lymphoblastic leukemia cells are capable of inducing
primary T cell responses in vivo. ELISPOT assays were performed
measuring IFN-g secretion from mice that had been injected with
104 live male NSTY cells or live male AML-m cells. Ten days after
leukemia cell injection spleen cells were removed and 106 spleen cells
were placed in each well. HY peptides or irrelevant control peptides
were also added to eachwell.HY specific spots5 (spots inHYpulsed
wells) – (spots in irrelevant peptide pulsed wells). One of 2 similar ex-
periments is presented. The assay was performed in triplicate for
each animal. ‘‘C57’’ indicates the animal was a normal female
C57BL/6 mouse. ‘‘NSTY-6’’ and ‘‘NSTY-7’’ are male bcr/abl1,
INK4A/ARF null acute lymphoid leukemia lines that were indepen-
dently derived from male INK4A/ARF null mice. ‘‘AML-m’’ is
a male bcr/abl1 AML line from a mouse that does not have the
INK4A/ARF deletion. ‘‘n’’ is the number of mice in each group.
The mean is presented, and error bars represent standard error of
the mean. A t test was used to compare mean spots in leukemia-in-
jected groups versus no leukemia group; P \ .05 for each of the
groups injected with leukemia.that vaccines or adoptive cellular immunotherapies
directed against mHA might be useful under some cir-
cumstances.However, still undefined are those circum-
stances in which this might be feasible. One hypothesis
that is emerging fromour studies is that relative kinetics
of leukemia and T cell growth may be critical in deter-
mining the window of opportunity for immune inter-
vention. In humans, ineffective unmanipulated GVL
maynot be from intrinsic resistance to immune control,
but may be from leukemia cell proliferation outpacing
in vivo generated anti-mHA T cell responses. The
INK4A/ARFmutation prevents cell cycle exit, produc-
ing shorter doubling times. Thus, effective immune
control of such acute leukemias may require not only
T cells that recognize leukemia cells in vivo but also
agents that reduce leukemia growth rates untilT cell re-
sponses peak kinetically. We are evaluating a variety of
agents including conventional antimetabolites and leu-
kemia specific tyrosine kinase inhibitors for their im-
pact on the balance between generation of anti-mHA
immune responses and leukemia population growth.
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